Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 16.: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 6: | Line 6: | ||
16. | 16. | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00072-Ins-her ++ TAG-00340-Req-nfo ++ TAG-00017-Spo-die ++ TAG-00018-Inv-die | ||
| | |RefModule=5 | ||
| | |RefUnit=5.5.0 | ||
}} | }} | ||
| Line 16: | Line 16: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 5 — Unit 5.5.0 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 34: | Line 37: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00072-Ins-her|Insurance]], [[Glossary:TAG-00340-Req-nfo|Requirements]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00018-Inv-die|Investigator]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 — Unit 5.5.0 |
| Scope | HM |
| Document part | Schedule 1
Part 2 16. |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Insurance, Requirements, Sponsor, Investigator |
| Comment | Indemnity and insurance provision requirements |
Content
CONDITIONS AND PRINCIPLES WHICH APPLY TO ALL CLINICAL TRIALS […] 16. Provision has been made for insurance or indemnity to cover the liability of the investigator and sponsor which may arise in relation to the clinical trial.
